3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Cholangiocarcinoma
3
Liver Neoplasms
2
Biliary Tract Neoplasms
2
Acrocephalosyndactylia
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Neoplasms
1
Carcinoma, Transitional Cell
1
Bile Duct Neoplasms
1
Interventions
pemigatinib
6
infigratinib
3
erdafitinib
2
derazantinib
2
Rogaratinib
2
pembrolizumab
1
lenvatinib
1
exemestane
1
brivanib
1
atezolizumab
1
Rabeprazole
1
Irinotecan
1
INCB 54828-101
1
Gemcitabine
1
Fulvestrant
1
E-3810
1
Drug Combinations
1
Carboplatin
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Acrocephalosyndactylia
×
derazantinib
×
Clear all
NCT04604132
2024-04-04
FIDES-03
Basilea Pharmaceutica
Phase 1/2
Terminated
47 enrolled
22 charts
NCT04045613
2023-10-13
FIDES-02
Basilea Pharmaceutica
Phase 1/2
Completed
95 enrolled
25 charts